Seeking Alpha

GlaxoSmithKline's (GSK +0.1%) lung treatment Relovair proved successful in two six-month phase...

GlaxoSmithKline's (GSK +0.1%) lung treatment Relovair proved successful in two six-month phase III trials. GSK and partner Theravance (THRX -1.6%) hope Relovair will generate billions of dollars, but will wait for results from larger 12-month studies before filing for approval. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|